Immatics (IMTX) Stock Price, Quote, News & History | Benzinga

SPY761.26−0.26%QQQ707.87−0.27%BTC/USD—DIA518.00−0.21%GLD381.40−0.16%TLT80.06+0.01%

Immatics NV (IMTX) Stock Price, Quote, News & History

IMTXNASDAQ

Trade with Public

Trade with Public

$6.73

-0.41-5.74%

Last update: Oct 16, 4:27 PM

$6.73

-0.41-5.74%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$7.19

Close

$6.73

Volume / Avg.

1.15M / 645.24K

Day Range

$6.65 - $7.19

52 Wk Range

6.73 - 12.41

Market Cap

$1.02B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

3.36%

Days to Cover

4.15

Recent Immatics N.V. News

This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.

Avi Kapoor

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

Avi Kapoor

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Avi Kapoor

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits shown. Phase 3 trials are set to begin by December 2024.

Vandana Singh

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-205.87M

Investing Cash Flow (TTM)

57.49M

Financing Cash Flow (TTM)

119.12M

Free Cash Flow (TTM)

-209.62M

Capital Expenditure (TTM)

-3.75M

Net Change in Cash (TTM)

-29.25M

Analyst Trends and Forecast

1

Apr

1

May

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$599.80M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

19.78

PB Ratio (TTM)

2.43

Earnings Yield % (TTM)

-24.94%

Earnings Yield % (FWD)

-30.92%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.94

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$2.97M

Total Cash

$232.46M

Debt to Equity

0.04

Issuance of Debt (TTM)

-$2.97M

Repayment of Debt (TTM)

-$2.97M